• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet acquires assets of Automated Glucose Control for $25M

February 14, 2023 By Sean Whooley

Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]
Insulet (Nasdaq:PODD) announced today that it acquired the assets of Automated Glucose Control, a developer of insulin delivery technology.

This marks the second asset buy in as many days for Insulet. Yesterday, the company picked up automated insulin delivery patents from Bigfoot Biomedical. Both acquisitions cost the company $25 million.

Palo Alto, California-based Automated Glucose Control (ACG) focuses on developing and commercializing best-in-class automated insulin delivery (AID) technology. Insulet develops its own AID platform, with the Omnipod 5 representing the latest iteration, having received FDA clearance last year.

Acton, Massachusetts-based Insulet entered into a license agreement and partnership with ACG in 2016. This agreement centered around patents and IP ACG licensed from the Dr. Francis J. Doyle III laboratory at the University of California, Santa Barbara.

Dr. Jennifer Schneider and Dr. Thomas Peyser co-founded ACG. They consulted with Insulet with respect to the licensed technology as part of Omnipod 5’s development. Insulet’s acquisition of assets includes the license from the University of California and other IP.

“We’ve enjoyed a productive relationship with AGC as we developed Omnipod 5 and continue to make significant advancements in the development of automated insulin delivery technology,” said Eric Benjamin, Insulet EVP of innovation, strategy, and digital products. “AGC played a critical role in facilitating the successful translation of research into industry by collaborating closely with Dr. Frank Doyle at the University of California Santa Barbara, and with Insulet.

“It is exciting to see technology come out of the research lab and mature into a commercial application that improves the lives of people with diabetes.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Technology Tagged With: Automated Glucose Control, Insulet

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS